Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Arda Ural
Innovation is moving at an unprecedented speed. Are you staying with it?
Innovation has been the lifeblood of human productivity and value creation since the Industrial Revolution.
Global Business Reports - Arda Ural
"The macro picture includes tailwinds such as declining rates, a peaceful transition of power and evolving FTC policies." PHD LIFE SCIENCES SECTOR LEADER, EY What impact with the 2024 election have on the Life Sciences industry? There will be a multi-layered impact of the elections starting with tariffs. Currently at 3%, tariffs could rise to 26% or more. These rates could go higher for China, Mexico and Canada.
Global Business Reports - Arda Ural
"The biotech sector has room to grow. Oncology, blood disorders, immunology, inflammation, rare diseases, and neurology are key therapeutic areas attracting capital and fostering innovation." PARTNER & AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES AND WELLNESS, EY After the JP Morgan Conference in January, how do you assess the health of the life sciences industry headed into 2024?
Council Post: What Got The Pharma Industry Here Won’t Get It There: Navigating A Complex Path Forward
Arda Ural, PhD | EY Americas Industry Markets Leader, Health Sciences and Wellness. The economic outlook for 2024 seems to be stuck between a persistent labor market, stronger-than-expected consumer spending and stubborn inflation that is not dropping fast enough for the Federal Reserve to feel comfortable to start tapering its short-term borrowing rates.
Can AI Help Pharma Overcome Its Formidable Growth Gap
Guest Column | December 14, 2023 By Arda Ural, PhD In the post-pandemic era, the pharmaceutical industry is facing some unfavorable secular trends. This complex environment has multiple forces putting pressure on the industry: Loss of patent exclusivity for many of the most profitable biologics, potentially resulting in more than $300 billion in lost revenue between 2023 and 2028, according to Evaluate Pharma and EY analysis.
09.14.23 -- Biosimilars Forum Statement On CMS Announcement Of Drug Negotiation List
Over the past 18 months, biotech has undergone a major transformation, down from the “sugar high” of the biotech bull market and steady flow of capital in the early pandemic years. Arda Ural of Ernst & Young provides key tips for your biotech to survive and thrive during the current market correction until investment in the sector cycles back to more prosperous times.
08.07.23 -- Is Your CDMO Relevant? How To Find Out
Welcome to the redesigned newsletter! In addition to having a new look, the newsletter will now be delivered daily, and each issue will focus on a specific therapeutic modality. On Mondays and Thursdays, we'll cover outsourcing. On Tuesdays, . And on Wednesdays and Fridays, . Update your topic preferences to receive only the newsletter(s) of interest to you.
Will You Sink, Survive, Or Thrive In This Biotech Market Correction?
By Arda Ural, EY Over the past 18 months, biotech has undergone a major transformation, down from the “sugar high” of the biotech bull market and steady flow of capital in the early pandemic years. And looking from the past to the future, both biotechs and Big Pharma must address innovation deficits and search for new revenues to offset the coming wave of patent expirations.
Will You Sink, Survive, Or Thrive In This Biotech Market Correction? Original
By Arda Ural, EY Over the past 18 months, biotech has undergone a major transformation, down from the “sugar high” of the biotech bull market and steady flow of capital in the early pandemic years. And looking from the past to the future, both biotechs and Big Pharma must address innovation deficits and search for new revenues to offset the coming wave of patent expirations.
05.11.23 -- How Can Life Sciences Navigate M&A In 2023
By A. Noorani, C. Fanelli, D. Ludlow, and R. Pai, Sidley Austin LLP We are seeing a significant increase in manufacturing facility inspections by the FDA and other health authorities globally. We are also seeing an uptick in whistleblower complaints. Why? And how can you navigate it? This article examines the issue.
04.12.23 -- Transitioning From Monoclonal Antibody To AAV Separation Science
By Adam L. Washburn, Eli Lilly and Company Separation scientists jumping from mAbs to AAV inherently have advantages, but familiarity can also present roadblocks. Here are a few tips on leveraging past experience with mAbs when developing AAV gene therapy products.
04.12.23 -- A Cell Therapy Development Strategy
By Adam L. Washburn, Eli Lilly and Company Separation scientists jumping from mAbs to AAV inherently have advantages, but familiarity can also present roadblocks. Here are a few tips on leveraging past experience with mAbs when developing AAV gene therapy products.
04.12.23 -- How Can Pharma Navigate M&A In 2023?
By Arda Ural, Ph.D., EY As we close out the first quarter of 2023, let's take a look at how life sciences executives can conduct better M&A deals despite this unpredictable business environment.
04.10.23 -- Navigating Biotech M&A In 2023?
Get more Bioprocess insight with our FREE newsletter Newsletter | April 6, 2123 By Arda Ural, Ph.D., EY Now that the first quarter of 2023 is in the books, let's take a look at how life sciences executives can conduct better M&A deals despite this unpredictable business environment. LyGenesis is developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs.
04.04.23 -- Effectively Navigate M&A In 2023
By Arda Ural, Ph.D., EY As we close out the first quarter of 2023, let's take a look at how life sciences executives can conduct better M&A deals despite this unpredictable business environment.
03.30.23 -- The Potential Of RNA Exon Editing
Article | By Brianna Barrett, Ph.D., and Danielle Sexton, Ph.D., Forge Biologics A platform approach with the flexibility to adapt to individual client needs can provide a head start on development that saves both time and money.
How Can Life Sciences Navigate M&A In 2023?
By Arda Ural, Ph.D., EY The past three years have seen incredible tumult across the life sciences sector, from record cash flowing into biotechs to pharma’s herculean effort to develop COVID-19 vaccines and therapeutics and to the steepest bull market in memory. As we close out the first quarter of 2023, it’s clear that what got us here won’t get us there.
How Can Life Sciences Navigate M&A In 2023? Original
By Arda Ural, Ph.D., EY The past three years have seen incredible tumult across the life sciences sector, from record cash flowing into biotechs to pharma’s herculean effort to develop COVID-19 vaccines and therapeutics and to the steepest bull market in memory. As we close out the first quarter of 2023, it’s clear that what got us here won’t get us there.
10.05.22 -- Cell & Gene Best Of September
Hello readers, I’m happy to bring you September’s most-clicked articles. Enjoy! Erin Harris, editor in chief
09.29.22 -- EMA Releases Statement Supporting Biosimilar Interchangeability In EU
By Kip Wolf, X-Vax Technology, @KipWolf This article is the first in a five-part series providing contemporary, practical, and useful examples of data integrity within each of the five traditional principles of ALCOA. This article centers on A: Attributable.
09.21.22 -- 5-Year Biotech Lookback & What It Bodes For Tomorrow
Article | By Justin A. Divan, Pfizer CentreOne A CDMO that can optimize your API synthesis early during technology transfer will reduce the risk of delay or failure. That will also help your molecule run more efficiently in their plant. Article | By William C.
09.06.22 -- Looking Ahead in Biotech
Article | By Jonathan Carson, RoosterBio Learn why allogeneic MSCs could be a favorable option in comparison with autologous MSCs. Article | By Steven Ng and Spencer Bolte, Automated Systems of Tacoma, Inc. Robotic aseptic fill/finish equipment offers many benefits to modern facilities, including flexibility to adjust to future growth and the speed to market necessary for today’s changing industry.
Biotech In 2016–2022 & Looking Ahead Original
By Arda Ural, Ph.D., EY The last five years have been disruptive regardless of sector, yet biotech managed to weather the storm, demonstrating resiliency and innovation despite both intrinsic and extrinsic challenges. In 2017, when EY last published a comprehensive analysis of the U.S. and European biotech sectors, looming issues included the impact of Brexit and the intensifying U.S. debate over the future of healthcare.
AI, machine learning transform life sciences industry
Today, the life sciences industry is at a critical inflection point. Its public profile has elevated due to its success at quickly developing vaccines to combat the COVID-19 pandemic. It has also built up a lot of trust. Despite the persistent issue of vaccine hesitancy, health — including life sciences — rose up in the rankings to become the second most trusted sector after technology, according to the 2021 Edelman Trust Barometer.
06.23.22 -- EMA Accepts Sandoz's Proposed High Concentration Formulation of Humira Biosimilar
By Arda Ural, Ph.D., EY The life sciences industry is facing a significant slowdown due to patent expirations. Many organizations have not established a robust enough pipeline to overcome the revenue to be lost. To bridge this innovation gap, pharma CEOs will need to expand their use of alliances, in tandem with bolt-on M&A, as a pipeline booster strategy.
Biotech industry delivers impressive innovation during an era of globa
By Arda Ural, PhD, EY Americas Industry Markets Leader, Health Sciences and Wellness. The 32nd edition of EY’s Beyond borders report found that despite global upheavals, including geopolitical complexities and the COVID-19 pandemic, the US and European biotechnology industries have not only stayed on course, but thrived on innovation.
06.03.22 -- Risk Mitigation In Bio Manufacturing
By Arda Ural, Ph.D., EY The life sciences industry is facing a significant slowdown due to patent expirations. Many organizations have not established a robust enough pipeline to overcome the revenue to be lost. To bridge this innovation gap, pharma CEOs will need to expand their use of alliances, in tandem with bolt-on M&A, as a pipeline booster strategy.
05.22.22 -- Biopharma Partnerships: The Key To Filling The Life Sciences Innovation Gap
By Arda Ural, Ph.D., EY The life sciences industry is facing a significant slowdown due to patent expirations. Many organizations have not established a robust enough pipeline to overcome the revenue to be lost. To bridge this innovation gap, pharma CEOs will need to expand their use of alliances, in tandem with bolt-on M&A, as a pipeline booster strategy.
05.19.22 -- Biopharma Partnerships: The Key To Filling The Life Sciences Innovation Gap
By Arda Ural, Ph.D., EY The life sciences industry is facing a significant slowdown due to patent expirations. Many organizations have not established a robust enough pipeline to overcome the revenue to be lost. To bridge this innovation gap, pharma CEOs will need to expand their use of alliances, in tandem with bolt-on M&A, as a pipeline booster strategy.
Biopharma Partnerships: The Key To Filling The Life Sciences Innovation Gap
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Guest Column | May 18, 2022 By Arda Ural, Ph.D., EY After overcoming challenges posed by the pandemic, biopharma continues to face headwinds caused by more foundational issues that hinder growth. Although the industry is facing a significant slowdown due to biological products' patent expirations, many organizations have not established a robust enough pipeline to overcome the revenue to be lost.
Biopharma Partnerships: The Key To Filling The Life Sciences Innovation Gap
Get more pharma manufacturing insight with our FREE newsletter sign me up Guest Column | May 18, 2022 By Arda Ural, Ph.D., EY After overcoming challenges posed by the pandemic, biopharma continues to face headwinds caused by more foundational issues that hinder growth. Although the industry is facing a significant slowdown due to biological products' patent expirations, many organizations have not established a robust enough pipeline to overcome the revenue to be lost.
04.14.22 -- BioPharma Deal-Making In 2022: Key Trends
By Arda Ural, Ernst & Young Strategic partnerships and alliances in biopharma have become an even more important means of accessing new capabilities. This article examines key recent trends in biopharma deal-making and M&A, and how those will inform related activities in 2022. By Scott Strom, DPR Construction As the life sciences workforce has increased, companies need more space to accommodate them.
03.31.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Desline Barber, IDT Biologika Lyophilization offers some alluring advantages in today’s complex market, but its challenges require innovation and expertise to surmount. White Paper | By Brian Anderson, AbbVie When executed properly, hot melt extrusion (HME) advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.
03.28.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Desline Barber, IDT Biologika Lyophilization offers some alluring advantages in today’s complex market, but its challenges require innovation and expertise to surmount. White Paper | By Brian Anderson, AbbVie When executed properly, hot melt extrusion (HME) advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.
03.20.22 -- Biopharma Deal-Making In 2022: Key Trends
By Paul Priebe By Michael Lally By Ahmed Besheer By Gillian Miller and Beth Kendsersky By Brian Curran By Frank Ritacco and Daniel Baskind By Ana Ladino By Christine Banaszek By Linnea Troeng, Matthew Townsend, Oliver Hardick, Jinyu Zou, and Tuomo Frigard By Kerstin Bernström, Nora Lieske, Dorthea Gjølberg, Ida Caroline Schrøder, Grethe Økern, HuiZhang, Tuva Holt Hereng, Ulrike Rehn, and Øystein Åmellem Lonza Wilson Tool Mettler-Toledo Product Inspection Automated Systems of Tacoma, Inc. Catalent
03.15.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Deanna Mudie, Ph.D., Lonza With so many different media available that vary widely in properties and composition, it is important to know how to select a dissolution media that can effectively test formulation robustness. Article | By Chris Rombach, Asahi Kasei Bioprocess The rapidly growing market for oligonucleotide manufacturing represents an opportunity for investors and pharma companies that wish to produce novel pharmaceutical products and therapies.
Biopharma Deal-Making In 2022: Key Trends
By Arda Ural, Ernst & Young A decade ago, our teams at EY created the Firepower Index to understand how life sciences companies were most likely to use M&A to drive portfolio growth. At the time, we had no idea Firepower, which we define as the capacity for dealmaking based on the strength of the balance sheet, would ignite so much interest — or be so broadly adopted. Fast forward to 2022, and we now believe it’s too limiting to define Firepower strictly in terms of M&A.
Biopharma Deal-Making In 2022: Key Trends
By Arda Ural, Ernst & Young A decade ago, our teams at EY created the Firepower Index to understand how life sciences companies were most likely to use M&A to drive portfolio growth. At the time, we had no idea Firepower, which we define as the capacity for dealmaking based on the strength of the balance sheet, would ignite so much interest — or be so broadly adopted. Fast forward to 2022, and we now believe it’s too limiting to define Firepower strictly in terms of M&A.
Biopharma Deal-Making In 2022: Key Trends
By Arda Ural, Ernst & Young A decade ago, our teams at EY created the Firepower Index to understand how life sciences companies were most likely to use M&A to drive portfolio growth. At the time, we had no idea Firepower, which we define as the capacity for dealmaking based on the strength of the balance sheet, would ignite so much interest — or be so broadly adopted. Fast forward to 2022, and we now believe it’s too limiting to define Firepower strictly in terms of M&A.
11.02.21 -- Inside Gene Therapy & AADC Deficiency
Newsletter | November 2, 2021 By Alex Zuluaga and Arda Ural, Ernst & Young This article examines the considerations you should make when weighing if a special purchase acquisition company (SPAC) is the right option for your company. By Irina A. Anselm, Boston Children's Hospital In AADC deficiency, dopamine is not produced in the part of the brain called the putamen, which is, therefore, a prime target for gene therapy. Article | By Barbara Gilmore, Frost & Sullivan, Bio-Rad Laboratories, Inc.
10.16.21 -- 9 Pitfalls To Avoid In Data Integrity In Pharmaceutical And Device Development & Operations
Newsletter | October 16, 2021 By Peter H. Calcott, Ph.D., Calcott Consulting LLC Cytiva By Alex Zuluaga and Arda Ural, Ernst & Young By Matthew Pillar, Editor, BioProcess Online By Kaspar van den Dries By Paul Magreta By Paul Belcher and Martin Teichert By Chris Howell and Brian Kunz, Director By Liam Takahashi By Kimberly Shepard, Ph.D. Thermo Fisher Scientific MilliporeSigma MilliporeSigma Entegris, Inc. JSR Life Sciences FUJIFILM Wako Chemicals U.S.A. Corp.
10.14.21 -- Is A SPAC The Right Option For Your Biotech?
Newsletter | October 14, 2021 By Alex Zuluaga and Arda Ural, Ernst & Young This article examines the considerations biotech companies should make when weighing if a special purpose acquisition company (SPAC) is the right option for them. By Cell & Gene Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and more.
10.14.21 -- Is A SPAC The Right Option For Your Biotech?
Article | By Fran L DeGrazio, West Pharmaceutical Services, Inc. As the benefits of delivering biologics drugs as part of a combination product platform are realized, this trend toward self-administration will continue to grow. Article | By Paul Jorjorian, Thermo Fisher Scientific Keeping pace with the market dynamics transforming the biologics space requires a focus on innovation and access to the integrated resources necessary to support it.
Is A SPAC The Right Option For Your Biotech Or Emerging Pharma Company
By Alex Zuluaga and Arda Ural, Ernst & Young As biotech and emerging pharma companies weigh their options for raising capital, the special purpose acquisition company (SPAC) has become an increasingly popular path to the public markets.
Is A SPAC The Right Option For Your Biotech Or Emerging Pharma Company
By Alex Zuluaga and Arda Ural, Ernst & Young As biotech and emerging pharma companies weigh their options for raising capital, the special purpose acquisition company (SPAC) has become an increasingly popular path to the public markets.
Is A SPAC The Right Option For Your Biotech Or Emerging Pharma Company
By Alex Zuluaga and Arda Ural, Ernst & Young As biotech and emerging pharma companies weigh their options for raising capital, the special purpose acquisition company (SPAC) has become an increasingly popular path to the public markets.
Is A SPAC The Right Option For Your Biotech Or Emerging Pharma Company
By Alex Zuluaga and Arda Ural, Ernst & Young As biotech and emerging pharma companies weigh their options for raising capital, the special purpose acquisition company (SPAC) has become an increasingly popular path to the public markets.
Bolt-On Acquisitions: Key Considerations For Life Science Executives
By Arda Ural Given the uncertainty of the past year, it’s no surprise that global M&A plummeted in 2020. But despite the turbulence, total liquidity in the market remained robust and relatively untouched, and one year later, thanks to scientific innovation, we now have a much brighter outlook for market activity. In fact, our research shows that 43% of life science executives plan to actively pursue acquisitions in the next 12 months.
2021: A “Tale of Two Cities” for the Pharma Industry
Uncertainty was the prevailing theme of 2020 across nearly every sector and business function of the life sciences industry. The pandemic’s unpredictability and economic turbulence halted business plans, scrambled supply chains, and turbo-charged digital transformation. Throughout the pharmaceutical industry, the rapid development of vaccines and therapeutics has upended pipeline plans and transformed product portfolios.
How life sciences executives can rally teams to achieve M&A synergies
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. EY | Assurance | Tax | Transactions | Advisory About EY EY is a global leader in assurance, tax, transaction and advisory services.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Arda
Contact Arda, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack